One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin

被引：20
作者：
Lippi, Giuseppe [1 ]
Franchini, Massimo [2 ]
Favaloro, Emmanuel. J. [3 ]
机构：
[1] Univ Verona, Sez Chim Clin, Dipartimento Sci Morfol Biomed, I-37134 Verona, Italy
[2] Univ Parma, Serv Immunoematol & Trasfus, Azienda Osped, I-43100 Parma, Italy
[3] Westmead Hosp, Dept Haematol, ICPMR, Westmead, NSW 2145, Australia
来源：
BLOOD COAGULATION & FIBRINOLYSIS | 2009年 / 20卷 / 01期
关键词：
activated partial thromboplastin time; clotting assay; factor V; haemophilia; therapy; THROMBIN GENERATION; HEMOPHILIA-A; CONCENTRATE; PLASMA; STANDARD; COAGULATION;
D O I：
10.1097/MBC.0b013e32831bc324
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 3
页数：3
相关论文
共 28 条
  • [1] Treating haemophilia A with recombinant blood factors: a comparison
    Ananyeva, N
    Khrenov, A
    Darr, F
    Summers, R
    Sarafanov, A
    Saenko, E
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (05) : 1061 - 1070
  • [2] Discrepancies in potency assessment of recombinant FVIII concentrates
    Barrowcliffe, TW
    Raut, S
    Hubbard, AR
    [J]. HAEMOPHILIA, 1998, 4 (04) : 634 - 640
  • [3] Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations
    Barrowcliffe, TW
    Raut, S
    Sands, D
    Hubbard, AR
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03) : 247 - 255
  • [4] Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII
    Brinkhous, K
    Sandberg, H
    Widlund, L
    Read, M
    Nichols, T
    Sigman, J
    Oswaldsson, U
    Schaub, RG
    Mikaelsson, M
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03) : 269 - 272
  • [5] A blinded in vitro study with Refacto® mock plasma samples:: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution
    Caron, C
    Dautzenberg, MD
    Delahousse, B
    Droulle, C
    Pouzol, P
    Dubanchet, A
    Rothschild, C
    [J]. HAEMOPHILIA, 2002, 8 (05) : 639 - 643
  • [6] ReFacto®1 and Advate®2:: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A
    Di Paola, J.
    Smith, M. P.
    Klamroth, R.
    Mannucci, P. M.
    Kollmer, C.
    Feingold, J.
    Kessler, C.
    Pollmann, H.
    Morfini, M.
    Udata, C.
    Rothschild, C.
    Hermans, C.
    Janco, R.
    [J]. HAEMOPHILIA, 2007, 13 (02) : 124 - 130
  • [7] Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
    Ettingshausen, C. Escuriola
    Kreuz, W.
    [J]. HAEMOPHILIA, 2006, 12 : 102 - 106
  • [8] Potency estimation of recombinant factor VIII: effect of assay method and standard
    Hubbard, AR
    Bevan, SA
    Weller, LJ
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) : 533 - 536
  • [9] Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays
    Ingerslev, J
    Jankowski, MA
    Weston, SB
    Charles, LA
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (04) : 623 - 628
  • [10] A collaborative study to establish a Korean Standard for factor VIII:C concentrate
    Kang, HN
    Kim, SN
    Lee, SH
    Hong, SH
    [J]. THROMBOSIS RESEARCH, 2004, 113 (3-4) : 261 - 267
123